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Introduction
Global and national burden
Every five minutes, somebody dies from a snakebite. According to the World 
Health Organization (WHO), an estimated 5.4 million people get bitten 
worldwide every year and around 81,000 to 138,000 people die each year 
because of snake bites.[1] In Africa alone, 435,000 to 580,000 victims[2] suffer 
snakebite envenoming and South Sudan could be one of the countries with the 
highest incidence. However, snakebite still receives less attention globally than 
other Neglected Tropical Diseases (NTDs) and comprehensive programmes and 
efforts to provide care to snakebite patients are limited. 
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Abstract
Introduction: Snakebite is a neglected tropical disease affecting around five 
million people, causing more than 100,000 annual deaths, as well as serious 
disabilities; however, access to antivenom and high-quality programmatic care 
remain a global challenge. 
Objective: Due to the high burden of snakebite in South Sudan and the 
serious negative outcomes if left untreated, Médecins Sans Frontières (MSF) 
integrated snakebite care for the first time among its priorities and consolidated 
a programme in Agok Hospital. 
Method: We describe the history, implementation, and challenges of the MSF 
snakebite programme. 
Results: The number of snakebite patients at MSF Agok Hospital has increased 
each year. From 2013 to 2019, MSF treated 2,005 snakebite patients. In 
2019 there were 527 snakebite admissions, 47% presented with severe 
envenomation, and one death. Puff adders, vipers and various cobras were 
identified. Agok Hospital gained understanding on the barriers and facilitators 
for the population to access care after a snakebite. MSF developed “snakebite 
diagnosis and treatment” algorithms, and provided clinical training, with the 
validation of national health authorities. Preventive activities were reinforced. 
Integration of surgical services was an essential programmatic aspect to 
monitor and treat complications. Challenges for implementation included a 
lack of easily available antivenoms in the international market. and the need of 
a strong supply chain and procurement systems. 
Conclusion: The delivery of healthcare towards snakebite patients can be 
successfully implemented when prioritized. Global efforts to improve access 
and quality of antivenoms and snakebite care could help removing Snakebite 
Envenoming from the Neglected Tropical Diseases list. 
Keywords: snakebite, snake, envenoming, antivenom, implementation, 
humanitarianism, secondary care, South Sudan
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Due to the high number of snakebite admissions, the 
limited availability of antivenom, and the serious negative 
outcomes if left untreated, Médecins Sans Frontières 
(MSF) has been implementing a Snakebite Programme 
as part of its medical activities at Agok hospital, in the 
Special Administrative Area of Abyei since 2014. 
MSF started nutritional medical activities in 2006 in the 
Abyei region. However, in 2008, conflict and violence 
displaced hundreds of thousands of people, including the 
MSF team, to the far south of the region. MSF started 
providing nutritional care and expanded activities to 
inpatient care in the town of Agok. Today, MSF’s hospital 
in Agok is the only secondary health care facility in the 
region, with a catchment population of some 140,000 
people. On average, the hospital provides more than 
4000 consultations and hospitalizes over 800 patients per 
month. 
In 2014, the MSF medical team at the hospital received 
an unexpected high number of snakebite patients (up 
to 90 in a single month) for which the organization was 
not fully prepared. This triggered the need to respond to 
the significant burden of a neglected disease in Agok and 
surrounding areas. In addition, pharmaceutical company 
Sanofi Pasteur announced in 2014 that it would stop 
producing the only recognized safe and efficient polyvalent 
antivenom, FAV-Afrique. MSF and the South Sudanese 
Ministry of Health therefore, implemented a study in 
partnership with Epicentre, MSF’s epidemiological 
research arm, to assess two new antivenoms and to increase 
access and quality of care for snakebites. Advocacy for 
better access to snakebite care and antivenom was also 
carried out nationally and internationally, including 
towards the WHO.[1-6] 
From January 2013 to December 2019, MSF treated 
2,005 snakebite patients in Agok, on average 286 per 
year. Hospital mortality due to snakebite dropped from 
3 deaths in 2014 (on arrival), to only 1 in 2019, despite 
recent doubling of admissions. Indeed in 2019 alone, 
MSF provided care for 527 snakebite victims, out of 
which 47% presented with severe envenoming.
Current implementation
Snakebite patients are considered priority cases in the triage 
area of the Emergency Room (ER). They are transferred 
to the Intensive Care Unit (ICU) if signs of envenoming 
are identified, or to the Inpatient Department for 24 
hour-observation if no alarming signs are present. Severely 
envenomed patients are kept in the ICU as long as the 
antivenom is indicated and receive continuous intensive 
monitoring to identify and respond to decompensation 
or shock, swelling, bleeding, neurological disorders, and 
severe adverse reactions due to the antivenoms, such as 
allergic or anaphylactic reactions (10% mild, <1% severe). 
Surgery can be required in severe cases and is an essential 
component of the snakebite treatment programme. The 
hospital surgeons intervene for compartment syndrome 
(compression of the veins in the muscles due to swelling) 
or when gangrene is suspected. If needed, fasciotomies are 
performed, and unfortunately also amputations of toes, 
fingers, or feet when patients present late with advanced 
envenoming. At the hospital, snakebite injuries are the 
fifth leading cause of surgical intervention among all 
performed surgical interventions. In 2019, 66 procedures 
among the total 527 snakebite patients represented 9.4% 
of all surgical interventions. 
Figure 1. Snakebite admissions
Figure 2. A MSF nurse changes the dressing of Aluk Manut. ( © 
Fanny Hostettler / MSF)
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Aluk Manut, aged six, was bitten by a snake on her right 
leg. Aluk and her mother, Teresa Aluoc Majok, travelled 
150 km by public transport from Gogrial to get to the 
hospital in Agok, South Sudan. Aluk received three doses 
of antivenom and has had seven surgical interventions. 
(Figure 2) In figure 3, MSF physiotherapist Ngong Ngong 
provides physiotherapy to snakebite patients to prevent 
the total loss of function in their limbs. Sometimes, the 
severity of the pain means the physiotherapy must be 
performed under anaesthesia. Here, Awien Maguor, 
aged 10, was bitten on her arm by a snake while she 
was sleeping under her mosquito net. She received three 
doses of antivenom and has had more than ten surgical 
interventions.
Whole Blood Clotting Test (WBCT20) is the standard 
coagulation test method, as recommended by the WHO 
snakebite management guidelines. It can be performed 
immediately at the bedside with modest resources 
and has the advantage of giving results in 20 minutes. 
However, the method also presented some performance 
issues when utilized in a limited resource context due to 
implementation challenges. 
WBCT20 (sensitivity 94% and specificity 76%)[7] is 
systematically performed when patients are admitted into 
the ER, and again 6 and 24 hours after arrival. Clinical 
features indicating haemotoxicity are paramount to take 
diagnostic and treatment decisions regardless of confusing 
test results. 
Currently, there are two available antivenoms in the 
programme. The first, Equitab Plus by ICP (Costa Rica), 
is used to cover the majority of cytotoxic and haemotoxic 
envenoming cases according to MSF protocol. It was 
designed to neutralize the venom of Echis ocellatus, the 
West African carpet viper and its East African cousin 
Echis pyramidum, as well as Bitis arietans puff adders’ and 
Naja nigricollis spitting cobras’ venoms (the last 2 species 
are frequent in Agok). The second, SAIMR-Polyvalent, 
is reserved for the rare cases of neurotoxic envenoming 
or critically ill patients according to MSF protocol. It is 
effective against cobras’ (Naja), mambas’ (Dendroaspis), 
and some large vipers’ (including Bitis arietans frequent 
in Agok) venoms. These two antivenoms have proven 
successful in a clinical setting like Agok Hospital, mainly 
due to the training of medical staff in administering and 
evaluating the treatment.  
Between 2014 and 2016, MSF medical teams simplified 
the 2010 WHO guideline into a pocket guide for South 
Sudan. After consulting with the Ministry of Health 
and receiving authorizations by the Drug and Food 
Control Authority (DFCA), we introduced a syndromic 
protocol (Figure 4 and Table 1) and started importing 
the two previously mentioned antivenoms. By that time, 
all remaining stocks of the internationally recognized 
polyvalent antivenom FAV-Afrique (Sanofi) had been 
used up and the manufacturer had stopped producing it. 
Figure 3. MSF physiotherapist Ngong Ngong (left) provides physiotherapy to snakebite patients. (© Fanny Hostettler / MSF)
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Achievements and discussion
MSF has responded to the burden of snakebites, enforcing 
the supply of antivenom and the cold chain, reviewing 
and improving algorithms, and strengthening knowledge 
and skills to better diagnose and manage snakebites. As 
a result, the delivery of care through a comprehensive 
programme and adequate health care may be one of 
MSF’s major achievements when tackling one of the most 
neglected conditions in the world. 
The integration of surgical services has proven essential 
when responding to complicated cases and is one of the 
main assets of the snakebite programme in Agok. Logistics 
have also played an important part in the successful 
implementation of the programme. With the support 
of national authorities, antivenoms have been procured 
and imported, thus facilitating the complex supply chain 
process. Logistics actively maintain a cold chain to avoid 
ruptures in order to guarantee the availability of a safe 
antivenom. At the hospital, 24/7 power supply via diesel 
generators and solar panels has been installed. This shows 
that it is fundamental to have a multisectoral approach. 
Besides clinical interventions, a monitoring study has 
been implemented since April 2018, in collaboration with 
the South Sudanese Ministry of Health. It examines the 
use of Equitab Plus and SAIMR antivenoms, advancing 
the efforts to generate evidence and to increase access and 
quality of care for snakebites. The scientific aim of the 
study, approved by the Ministry of Health and Ethics 
Committee, is to monitor snakebite patients to describe 
all clinical symptoms, cure rates, and adverse reactions 
through regular clinical evaluations of vital signs, swelling 
size, clotting tests at 0, 6 and 24 hours, and neurological 
signs. We try to identify snake species by comparing 
patient descriptions of them with photographs.
So far, the community of Agok is receptive, positively 
accepting the research implementation and consenting 
to be enrolled. In part, this is due to the overall good 
acceptance of the local population towards the hospital 
during the last 10 years. 
Figure 4. MSF Agok Snakebite Protocol algorithm 
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● Spitting cobra Naja 
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joint,  
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failure, hypoxia - Coma 
or myocardial infarction.   
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Table 1: MSF Agok Snakebite syndromic classification
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Challenges and barriers
Agok is a flat land with seasonal swamps. Flooding due 
to heavy rain in the wet seasons displace snakes from 
their habitats (holes in the soil) to look for dry and raised 
land and this exposes people to bites while carrying out 
different activities such as farming, fetching water, fishing, 
or even sleeping indoors. 
The poverty level and vulnerability of the population 
also put some people at risk of snake bites. For instance, 
people cannot afford to buy protective gear such as boots 
or closed shoes. Rural paths can be dark, making it easy 
to accidentally tread on a snake. Some traditional house 
constructions are snake-prone, food storage is not always 
separated, attracting rodents that in turn attract snakes. 
Finally, sleeping on the ground without a mosquito net 
can also increase the risk of being bitten.[8]
Ensuring provision of antivenom is one of the most 
important challenges, particularly after the production of 
the “gold-standard” polyvalent FAV-Afrique antivenom 
was stopped in 2014 by Sanofi Pasteur. The last vial of 
FAV-Afrique expired in 2016. Since then, Equitab Plus 
(Costa Rica) and SAIMR (South Africa) antivenoms, 
also effective,[9] were successfully introduced in MSF’s 
Agok hospital but their extremely high price is a major 
constraint in ensuring their availability across primary 
healthcare centres more widely in South Sudan and 
elsewhere. The price of a vial of Equitab Plus is around 35 
USD and SAIMR is around 300 USD per vial. Three vials 
are needed for a standard treatment, and this dose may be 
repeated once or twice, depending on severity. The overall 
cost is therefore out of reach for the vast majority of health 
facilities and patients.  
Another significant challenge is the remoteness of the area 
and the long time it takes patients to reach the hospital. 
During the rainy season (July to November), bad roads and 
lack of transport make timely access to the hospital almost 
impossible. Delays can increase the risk of complications, 
long term sequelae, disabilities, and mortality. 
Local beliefs and traditions also influence the management 
of patients. Snakebite victims may delay seeking care due to 
preference of traditional medicine, causing complications 
which require additional care.[10] In some instances, 
patients are reluctant to receive surgical interventions 
even if strongly needed and recommended. Fasciotomies 
and amputations are understandably difficult to accept. 
Counselling and health education are provided to 
support patients in taking informed decisions. However, 
sometimes this is not enough and surgical procedures for 
severe complications are simply refused. It is important to 
find ways to address this in order to diminish the negative 
health outcomes of snakebites. 
Conclusions and recommendations
The medical and antivenom component of snakebite 
management is paramount, but a significant number 
of complications would not be addressed without 
integrated surgical services. It is therefore, important 
to gain acceptance of the local population for surgical 
interventions when required. 
The general implementation of the MSF snakebite 
programme has been successful and keeps improving 
thanks to standardized treatment protocols, close 
supervision, strong logistical and pharmaceutical teams 
overseeing the supply and cold chains, as well as the 
support from and collaboration with health authorities to 
facilitate the procurement of the antivenoms. 
Polyvalent antivenoms effective in treating envenoming 
from a broad number of snake species need to be made 
affordable and accessible to provide health providers, 
including in low-income settings, with the means to save 
the lives of snakebite victims. 
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Five people die of snakebites in Tonj East
RADIO TAMUZUJ TONJ EAST - 22 SEP 2020
At least five people including children have died from snakebites in Tonj East County of Warrap State since 
June, a local official said.
The floods that hit many parts of Warrap State have forced snakes to seek higher ground. That has led to 
more snakebites.
Albino Angok Majak, the Executive Director of former Luanyjang North County, told Radio Tamazuj on 
Tuesday that they had recorded about 13 cases of snakebites from June until 21 September.
“Five people have died since June until yesterday (Monday) when I received the fifth person who died due 
to snakebites,” Albino Angok said. “Those who included children and a pregnant mother, I have their 
names here with me.”
According to the World Health Organization (WHO), snakebite envenoming is responsible for thousands 
of deaths among rural populations globally every year.
The executive director said eight other people have recovered from the snakebites. He further said about 
15,000 households have been displaced from their homes by floods to higher ground within the area and 
that they are in dire need of humanitarian aid.
Angok said the floods have destroyed all the crops in the whole villages of Luanyjang, saying the situation of 
the displaced families is expected to worsen in the coming months if there is no support.
The local official calls upon humanitarian organizations to intervene before the humanitarian situation 
deteriorates further.
